Dermatology specialist Journey Medical (Nasdaq: DERM) has announced positive top-line results from two Phase III trials of its rosacea candidate, DFD-29, a formulation of minocycline hydrochloride.
Rosacea is a condition in which some of the blood vessels in the face become enlarged, giving a flushed appearance.
The company, a subsidiary of Floridian firm Fortress Biotech (Nasdaq: FBIO), is developing the candidate in collaboration with Indian generic drugmaker Dr Reddy's Laboratories (BSE: 500124).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze